[fr] Les glomérulopathies constituent une cause d'insuffisance rénale non négligeable. Les traitements cytotoxiques utilisés avec les corticostéroïdes pour induire la rémission de la protéinurie et stabiliser la fonction rénale, ainsi que pour prévenir la rechute, présentent des effets secondaires importants : infections, néoplasies secondaires, infertilité et alopécie, voire néphrotoxicité. Le mycophénolate mofétil (MMF), utilisé en prévention du rejet lors de la transplantation d'organes, présente des caractéristiques intéressantes dans ce contexte particulier. Son profil d'effets secondaires est aussi avantageux. La présente revue de la littérature montre que le MMF semble efficace dans la plupart des glomérulopathies, sous réserve de résultats encore assez limités qui demandent à être confirmés. [en] Glomerular diseases remain frequent causes of end-stage renal failure. Immunosuppressive drugs in association with corticosteroids induce remission of proteinuria and stabilize renal function, as well as prevent relapses, but are responsible for severe portential side-effects: infections, secondary malignancies, sterility and alopecia, and even nephrotoxicity. Mycophenolate mofetil (MMF), a well-known drug in transplantation, presents interesting characteristics potentially useful in the teatment of glomerulopathies. Moreover, its side-effect profile is safer. The present review of literature suggests that MMF is efficient for the treatment of glomerular disease, even if the results of the different studies remain limited and require further confirmation.
Steinberg AD, Steinberg SC. Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only. Arthritis Rheum 1991;34:945-50.
Houssiau FA, Vasconcelos C, D'Cruz D, et al. Immunosuppressive therapy in lupus nephritis:The Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 2002;46:2121-31.
** Ginzler EM, Dolley MA,Aranow C, et al. Mycophenolate mofetil or intravenous ciclophosphamide for lupus nephritis. N Engl J Med 2005;353:2219-28.
Chan TM, Li FK,Tang CS, et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangshou Nephrology Study Groupe. N Engl J Med 2000;343:1156-62.
Hu W, Liu Z, Chen H, et al. Mycophenolate mofetil versus cyclophosphamide therapy for patients with diffuse proliferative lupus nephritis. Chin Med J 2002;115:705-9.
** Moore RA, Derry S. Systematic review and meta-analysis of randomized trials and cohort studies of mycophenolate mofetil in lupus nephritis. Arthritis Res Ther 2006;8:R182.
Contreteras G, Pardo V, Leclercq B, et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004;350:971-80.
Bijl M, Horst G, Bootsma H, Limburg PC, Kallenberg CG. Mycophenolate mofetil prevents a clinical relapse in patients with systemic lupus erythematosus at risk. Ann Rheum Dis 2003;62:534-9.
Sloan RP, Schwartz MM, Korbet SM, et al. Long-term outcome in systemic lupus erythematosus membranous glomerulonephritis. Lupus Nephritis Collaborative Study Group. J Am Soc Nephrol 1996;7:299-305.
Mercadal L, Tezenas du Montcel S, Nochy D, et al, et le Groupe d'études néphrologiques en Ile de France. Factors affecting outcome and prognosis in membranous lupus nephropathy. Nephrol Dial Transplant 2002;17:1771-8.
Wilmer WA, Rovin BH, Hebert CJ, et al. Management of glomerular proteinuria:A commentary. J Am Soc Nephrol 2003;14:3217-32.
Moroni G, Maccario M, Banfi G, et al. Treatment of membranous lupus nephritis. Am J Kidney Dis 1998;31:681-6.
** Spetie DN, Tang Y, Rovin BH, et al. Mycophenolate therapy of SLE membranous nephropathy. Kidney Int 2004;66:2411-5.
Borba EF, Guedes LK, Christmann RB, et al. Mycophenolate mofétil is effective in reducing lupus glomerulonephritis proteinuria. Rhumatol Int 2006;26:1078-83.
Kasitanon N, Fine DM, Haas M, et al. Hydroxychloroquine use predicts complete renal remission within 12 months among patients treated with mycophenolate therapy for membranous lupus nephritis. Lupus 2006;15:366-70.
Strippoli GF, Manno C, Schena FP. An «evidence-based» survey of therapeutic options for IgA nephropathy:Assessment of criticism. Am J Kidney Dis 2003;41:112-39.
Tang S, Leung JC, Chan LY, et al. Mycophenolate mofetil alleviates persistent proteinuria in IgA nephropathy. Kidney Int 2005;68:802-12.
* Maes DB, Oyen R, Claes K, et al. Mycophenolate mofetil in IgA nephropathy: Results of a 3-year prospective placebo-controlled randomized study. Kidney Int 2004;65:1842-9.
Frisch G, Lin J, Rosenstock J, et al. Mycophenolate mofetil (MMF) vs placebo in patients with moderately advanced IgA nephropathy: A double-mind randomized controlled trial. Nephrol Dial Transplant 2005;20:2139-45.
Choi MJ, Eustace JA, Gimenez LF, et al. Mycophenolate mofetil treatment for primary glomerular diseases. Kidney Int 2002;61:1098-114.
Day CJ, Cockwell P, Lipkin GW, et al. Mycophenolate mofetil in the treatment of resistant idiopathic nephritic syndrome. Nephrol Dial Transplant 2002;17:2011-3.
Pesavento TE, Bay WH, Agarwal G, Hernandez RA, Jr, Hebert LA. Mycophenolate therapy in frequently relapsing minimal change disease that has failed ciclophosphamide therapy. Am J Kidney Dis 2004;43:e3-e6.
Mendizabal S, Zamora I, Berbel O, et al. Mycophenolate mofetil in steroid/cyclosporine-dependent/resistant nephrotic syndrome. Pediatr Nephrol 2005;20:914-9.
Cattran DC, Wang MM, Appel G, Matalon A, Briggs W. Mycophenolate mofetil in the treatment of focal segmental glomerulosclerosis. Clin Nephrol 2004;62:405-11.
Cattran DC. Membranous nephropathy: Quo vadis ? Kidney Int 2002;61:349-50.
Glassock RJ. Diagnosis and natural course of membranous nephropathy. Semin Nephrol 2003;23:324-32.
Torres A, Dominguez-Gil B, Carreno A, et al. Conservative versus immunosuppressive treatment of patients with idiopathic membranous nephropathy. Kidney Int 2002;61:219-27.
Miller G, Zimmerman R, Radhakrishnan J, Appel G. Use of mycophenolate mofetil in resistant membranous nephropathy. Am J Kidney Dis 2000;36:250-6.
Polenakovic M, Grcevska L, Dzikova S. Mycophenolate mofetil in treatment of idiopathic stages III-IV membranous nephropathy. Nephrol Dial Transplant 2003;18:1233-4.
du Buf-Vereijken PW, Wetzels JF. Mycophenolate mofetil (MMF) versus cyclophosphamide (CP) in patients with idiopathic membranous nephropathy (MN) and renal insufficiency (Abstract). J Am Soc Nephrol 2004;14:A341.
Jones G, Juszcak M, Kingdon E, et al. Treatment of idiopathic membranoproliferative glomerulonephritis with mycophenolate mofetil and steroids. Nephrol Dial Transplant 2004;19:3160-4.
Booth AD, Almond Mk, Burns A, et al. Outcome of ANCA-associated renal vasculites:A 5-year retrospective study. Am J Kidney Dis 2003;41:776-84.
Jayne D, Rasmussen N, Andrassy K, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003;349:36-44.
* Joy MS, Hogan SL, Jennette JC, Falk RJ, Nachman PH. A pilot study using mycophenolate mofetil in relapsing or resistant ANCA small vessel vascularites. Nephrol Dial Transplant 2005;20:2725-32.
Koukoulaki M, Jayne DR. Mycophenolate mofetil in antineutrophil cytoplasm antibodies-associated systemic vascularites. Nephron Clin Pract 2005;102:c100-c107.
Langford CA, Talar-Williams C, Sneller MC. Mycophenolate mofetil for remission maintenance in the treatment of Wegener's granulomatosis. Arthritis Rheum 2004;51:278-83.
Nowack R, Gobel U, Klooker P, et al. Mycophenolate mofetil for maintenance therapy of Wegener's granulomatosis and microscopid polyangiitis: A pilot study in 11 patients with renal involvement. J Am Soc Nephrol 1999;10:1965-71.
Garcia-Canton C, Toledo A, Palomar R, et al. Goodpasture's syndrome treated with mycophenolate mofetil. Nephrol Dial Transplant 2000;15:920-2.
* Segarra A, Amoedo ML, Martinez J, et al. Efficacy and safety of «rescue therapy» with mycophenolate mofetil in resistant primary glomerulonephritis - A multicenter study. Nephrol Dial Transplant 2007;22:1351-60.
Kamar N, Oufroukhi L, Faure P, et al. Questionnaire-based evaluation of gastrointestinal disorders in de novo renal-transplant patients receiving either mycophenolate mofetil or enteric-coated mycophenolate sodium. Nephrol Dial Transplant 2005;20:2231-6.